Theragenics Corporation is a medical device company serving the surgical products and prostate cancer treatment markets. The Company advanced its diversification strategy by investing over $100 million since May 2005 in three acquisitions that make up its surgical products division. The surgical segment manufactures and distributes wound closure, vascular access, and specialty needle products through Theragenics' subsidiaries, CP Medical located in Portland, Oregon, Galt Medical located in Garland, Texas, and NeedleTech Products located in Attleboro, Massachusetts. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, valved sheaths, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, and other needle-based products. This business segment serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental, urology, veterinary, pain management, endoscopy, and spine.
Theragenics' brachytherapy business manufactures and markets its premier product, the palladium-103 TheraSeed® device and I-Seed, an iodine-125 based device. Physicians implant these "seeds" during a one-time, minimally invasive procedure, usually performed on an outpatient basis, primarily to treat patients with localized prostate cancer. The Company's seeding devices have been used over the last 20 years to treat over 130,000 men for prostate cancer. Theragenics' brachytherapy business segment and its corporate headquarters are located in Buford, Georgia.
|
